Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.54 |
| ▸ | LPL | P06858 | 8/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19794893 | 0.94 | DGAT1 (0.53) | DGAT1LPLLIPGF11FFAR1 | |
| SCHEMBL1284745 | 0.92 | DGAT1 (0.58) | DGAT1LPLLIPGF11FFAR1 | |
| SCHEMBL22435592 | 0.88 | DGAT1 (0.55) | DGAT1LPLLIPGAPPMAPT | |
| SCHEMBL22534190 | 0.86 | DGAT1 (0.50) | DGAT1LPLLIPGMAPTCA1 | |
| SCHEMBL25475421 | 0.83 | DGAT1 (0.55) | DGAT1LPLLIPGAPPMAPT | |
| SCHEMBL2584006 | 0.83 | DGAT1 (0.58) | DGAT1LPLLIPGF11FFAR1 | |
| SCHEMBL29631065 | 0.83 | DGAT1 (0.58) | DGAT1LPLLIPGF11FFAR1 | |
| SCHEMBL14233737 | 0.83 | DGAT1 (0.39) | DGAT1APPMAPTSNCA | |
| SCHEMBL20120561 | 0.83 | DGAT1 (0.56) | DGAT1LPLLIPGFFAR1 | |
| SCHEMBL2066133 | 0.82 | DGAT1 (0.56) | DGAT1LPLLIPGF11FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9669107-B2 | Antibody-active agent conjugates and methods of use | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-06 | — | — | US | disclosed |
| US-9669107-B2 | Antibody-active agent conjugates and methods of use | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-06 | — | — | US | disclosed |
| US-20160213786-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2016-07-28 | — | — | US | disclosed |
| US-20160213786-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2016-07-28 | — | — | US | disclosed |
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2015-04-16 | — | — | US | disclosed |
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2015-04-16 | — | — | US | disclosed |
| US-20140187756-A1 | Methods of preparing antibody-active agent conjugates | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-07-03 | — | — | US | disclosed |
| US-20140187756-A1 | Methods of preparing antibody-active agent conjugates | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-07-03 | — | — | US | disclosed |
| US-20140161829-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-06-12 | — | — | US | disclosed |
| US-20140161829-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-06-12 | — | — | US | disclosed |
| US-20120308584-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213786-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FNTA, FCGRT, GGT1 | DGAT1 554/4885LPL 2624/4885LIPG 1786/4885 |
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FCGRT, CD47, FNTA | DGAT1 498/4885LPL 2316/4885LIPG 768/4885 |
| US-20140161829-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FNTA, FCGRT, CD47 | DGAT1 464/4885LPL 2479/4885LIPG 891/4885 |
| US-20140187756-A1 | Methods of preparing antibody-active agent conjugates | FNTA, GGT1, ICMT | DGAT1 271/4885LPL 2926/4885LIPG 1621/4885 |
| US-20120308584-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | FNTA, DNPEP, RCE1 | DGAT1 881/4885LPL 2154/4885LIPG 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.